Sofinnova Partners, a European venture capital firm with bases in Paris, London, and Milan, has announced the closing of its “Sofinnova Digital Medicine I” fund, amassing $200M (€190M). This new fund represents the largest early-stage digital medicine fund in Europe, surpassing its initial fundraising target.
The fund, led by Edward Kliphuis and Simon Turner, aims to advance the digital healthcare sector. It focuses on backing companies at the intersection of biology, data, and technology. Since its establishment, the fund has already invested in five companies, demonstrating its commitment to fostering transformative healthcare solutions.
Sofinnova’s Digital Medicine Strategy aligns with the current transformative wave in healthcare, supported by digital innovation. The fund’s primary investment areas include enabling technologies, analytics, and treatment. This approach not only provides financial resources but also extends expertise and access to Sofinnova’s extensive healthcare networks. The goal is to empower entrepreneurs to address global health challenges and improve patient outcomes worldwide.
Among the recent investments of the Digital Medicine fund are L’école AI and Betteromics. L’école AI, founded by a former Twitter Cortex team member, focuses on simplifying the deployment of deep-learning systems in life sciences through machine teaching technology. Betteromics, known as the “Omics AI Cloud,” integrates diverse health and omics data into a unified platform, enhancing data accessibility and reliability.
Edward Kliphuis, Partner, said: “In just a few months since launching this strategy, we’ve executed five investments into transformative companies, including Kiro, BioCorteX, deepc, L’école AI, and Betteromics, which are fusing state-of-the-art computational methods with advanced biological innovations. Leveraging Sofinnova’s expertise and network, we serve as allies to digital medicine pioneers, enabling them to secure product-market fit and scale on a global stage.”
Simon Turner, Partner, said: “We bring Sofinnova’s deep healthcare expertise to entrepreneurs pioneering at the forefront of digital medicine where biology meets tech-industry approaches like rapid product iteration and accelerated commercialization. Our goal is to support innovators developing disruptive solutions for patients and health systems.”
Sofinnova Partners continues its mission of being a pivotal player in the life sciences venture capital landscape. The firm, established in 1972, has a long-standing history in the industry, with €2.5 billion AUM, more than 50 years of experience and over 500 companies backed.
